Some were having problems with Leo responses (supposed responses) not being in bold so I underlined the responses from Leo. Some of the questions didn't come thru but it is easy to figure them out from the responses.
I just received a response from Leo, wanted to share immediately. His responses in bold:
Shareholders need to know what is happening with the company, given the unexplained problem with getting Prurisol results, We expect to update shareholders shortly. The anticipated sequence of news will be a) Data Lock, and b) thereafter, top-line results.
the toxic capital raise, We sold stock at a fixed price. Albeit low but we needed funds for production of Brilacidin for further studies and other clinical trial payables.
and lack of BTD or deal for Brlacidin-OM despite "excellent" results and saying negotiations were underway. Please anticipate our update as all this is being worked on.
The growing concern is that the company may have misled investors and fumbled the Prurisol trial. The trial will be unblinded shortly. It's a function of company resources allocated to each product.
Was relieved to get this response. We're never gonna hear what happened with P delay nor full truth of capital raise, but the important things are still moving to fruition.
I just received a response from Leo, wanted to share immediately. His responses in bold:
Shareholders need to know what is happening with the company, given the unexplained problem with getting Prurisol results, We expect to update shareholders shortly. The anticipated sequence of news will be a) Data Lock, and b) thereafter, top-line results.
the toxic capital raise, We sold stock at a fixed price. Albeit low but we needed funds for production of Brilacidin for further studies and other clinical trial payables.
and lack of BTD or deal for Brlacidin-OM despite "excellent" results and saying negotiations were underway. Please anticipate our update as all this is being worked on.
The growing concern is that the company may have misled investors and fumbled the Prurisol trial. The trial will be unblinded shortly. It's a function of company resources allocated to each product.
Was relieved to get this response. We're never gonna hear what happened with P delay nor full truth of capital raise, but the important things are still moving to fruition.
4
